Time-Limited Zanubrutinib Plus Venetoclax: MRD-Guided Outcomes from SEQUOIA Arm D

Summary: A recent study brings great news for patients with chronic leukemia (CLL/SLL). The SEQUOIA trial tested a combination of two drugs, zanubrutinib and venetoclax. Instead of taking medicine forever, patients could actually stop their treatment once tests showed no signs of the disease. This "time-limited" approach worked incredibly well, even for patients with high-risk types of leukemia. After three years, nearly 90% of patients were still doing great without their disease getting worse. It means patients can get their lives back with safe, effective, and shorter treatments!

For more details, see rssapp-cancernetwork-com at cancernetwork.com/view/time-limited-zanubrutinib-plus-venetoclax-mrd-guided-outcomes-from-sequoia-arm-d (opens in new tab)